HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Human Pathology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0046-8177(00)80195-1PMID 10665910
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prognostic factors in gastric cancer.

  1998cited by this paper
• Changing patterns in the incidence of esophageal and gastric carcinoma in the United States

  1998cited by this paper
• Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma.

  1997cited by this paper
• Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis.

  1997cited by this paper
• HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.

  1997cited by this paper
• Expression of p53, PCNA, and C-erbB-2 in Barrett's Metaplasia and Adenocarcinoma

  1997cited by this paper
• Prognostic significance of HER‐2/neu gene amplification status by fluorescence in Situ hybridization of prostate carcinoma

  1997cited by this paper
• c-erbB-2 overexpression in the dysplasia/carcinoma sequence of Barrett's oesophagus.

  1995cited by this paper
• The Significance of c-erb B‐2 and p53 Immunoreactivity in Patients with Adenocarcinoma of the Esophagus

  1995cited by this paper
• Expression of c-erbB-2 oncogene product in Barrett's adenocarcinoma: pathological and prognostic correlations.

  1994cited by this paper
• Prognostic value of DNA ploidy and cerbB‐2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus

  1994cited by this paper
• Continuing climb in rates of esophageal adenocarcinoma: an update.

  1993cited by this paper
• Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group.

  1993cited by this paper
• Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction.

  1993cited by this paper
• Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.

  1993cited by this paper
• Amplification and over‐expression of the EGFR and erbB‐2 genes in human esophageal adenocarcinomas

  1993cited by this paper
• Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus.

  1992cited by this paper
• ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization.

  1992cited by this paper
• Immunohistochemical assay of neu/c-erbB-2 oncogene product in paraffin-embedded tissues in early breast cancer: retrospective follow-up study of 245 stage I and II cases.

  1991cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper
• The increasing frequency of adenocarcinoma of the esophagus

  1989cited by this paper
• Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading.

  1988cited by this paper

• Clinical Relevance of Tissue and Serum Human Epidermal Growth Factor Receptor 2 Expression in Patients With Esophageal Squamous Cell Carcinoma.

  2021cites this paper
• HER2-Directed Therapy in Advanced Gastric and Gastroesophageal Adenocarcinoma: Triumphs and Troubles

  2021cites this paper
• Biomarkers of Esophageal Cancers and Precancerous Lesions

  2021cites this paper
• Management of Locally Advanced Esophageal Cancer.

  2020cites this paper
• Prognostic and therapeutic molecular markers in the clinical management of esophageal cancer

  2020cites this paper
• Cancer of the Esophagus

  2020cites this paper
• Prognostic significance of Human epidermal growth factor receptor-2 expression in patients with resectable gastric adenocarcinoma

  2019cites this paper
• Lapatinib in combination with paclitaxel plays synergistic antitumor effects on esophageal squamous cancer

  2018cites this paper
• Predictive Marker: HER2 in Esophageal Adenocarcinoma.

  2018cites this paper
• Oesophagus: Neoplastic Patterns and Mimics

  2018cites this paper
• Systemic therapy for esophagogastric cancer: targeted therapies.

  2017cites this paper
• Epidemiologic Study of Human Epidermal Growth Factor Receptor 2 Expression in Advanced/Metastatic Gastric Cancer: an Assessment of Human Epidermal Growth Factor Receptor 2 Status in Tumor Tissue Samples of Gastric and Gastro-Esophageal Junction Cancer

  2017cites this paper
• Esophageal Cancer: Background and Clinical Evidence

  2017cites this paper
• HER2 expression in oesophageal carcinoma and Barrett's oesophagus associated adenocarcinoma: An Australian study.

  2016cites this paper
• Skeletal muscle metastasis from signet ring cell esophageal adenocarcinoma.

  2016cites this paper
• Tumor Immunotherapy of Esophageal and Gastric Cancers

  2015cites this paper
• Emerging mAbs for the treatment of esophagogastric cancer

  2015cites this paper
• Gastric cancer and the epoch of immunotherapy approaches.

  2015cites this paper
• 52. Barrett Esophagus and Esophageal Adenocarcinoma

  2015cites this paper
• Systemic therapy and targeted agents in advanced esophageal cancer

  2015cites this paper
• Molecular Medicine and Personalized Therapy for Breast Cancer Patients

  2015cites this paper
• Brain Metastases from Esophageal Cancer in the Presence of HER-2 Overexpression

  2015cites this paper
• A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage

  2014cites this paper
• Genome‐wide analysis of esophageal adenocarcinoma yields specific copy number aberrations that correlate with prognosis

  2014cites this paper
• Cancer of the Esophagus

  2014cites this paper
• Current strategies in chemoradiation for esophageal cancer.

  2014cites this paper
• HER2 status in Barrett's esophagus & esophageal cancer: a meta analysis.

  2014cites this paper
• Advances in biomarkers for esophageal cancer

  2013cites this paper
• Early Diagnostic Biomarkers for Esophageal Adenocarcinoma—The Current State of Play

  2013cites this paper
• New therapeutic strategies for squamous cell cancer and adenocarcinoma

  2013cites this paper
• Characterization of a Novel Tumorigenic Esophageal Adenocarcinoma Cell Line: OANC1

  2013cites this paper
• HER-2 Expression in Brain Metastases from Colorectal Cancer and Corresponding Primary Tumors: A Case Cohort Series

  2013cites this paper
• Expresión de Her2/neu en carcinoma gástrico en el área metropolitana de Bucaramanga en el periodo 2006 a 2009

  2013cites this paper
• Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastroesophageal junction

  2013cites this paper
• HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR -2 OVEREXPRESSION IN PATIENTS WITH GASTRIC AND OESOPHAGEAL ADENOCARCINOMA- A RETROSPECTIVE STUDY ON GHANAIAN CANCER PATIENTS WHO ATTENDED KORLE BU TEACHING HOSPITAL

  2013cites this paper
• Molecular Pathology of Barrett’s Metaplasia and Esophageal Adenocarcinoma

  2013cites this paper
• The significance of the HER-2 status in esophageal adenocarcinoma for survival: an immunohistochemical and an in situ hybridization study.

  2013cites this paper
• Amplification of Her-2/neu oncogene in GERD - Barrett's metaplasia – dysplasia - adenocarcinoma sequence.

  2013cites this paper
• HER2 status in gastric cancer: a comparison of two novel in situ hybridization methods (IQ FISH and dual color SISH) and two immunohistochemistry methods (A0485 and HercepTest™).

  2013cites this paper
• GERD—Barrett—Adenocarcinoma: Do We Have Suitable Prognostic and Predictive Molecular Markers?

  2013cites this paper
• Molecular biomarkers in esophageal, gastric, and colorectal adenocarcinoma.

  2013cites this paper
• Characterization of the timing and prevalence of receptor tyrosine kinase expression changes in oesophageal carcinogenesis

  2013cites this paper
• Concordance of HER2 status in primary tumour and lymph node metastases in patients with esophageal carcinoma.

  2013cites this paper
• Emerging tyrosine kinase inhibitors for esophageal cancer

  2013cites this paper
• Human epidermal growth factor receptor-2 in oesophageal cancers: an observational study.

  2012cites this paper
• Relative Prognostic Value of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Operable Oesophagogastric Cancer

  2012cites this paper
• Molecular basis of esophageal cancer development and progression.

  2012cites this paper
• Systematic Review and Meta-analysis of the Influence of HER2 Expression and Amplification in Operable Oesophageal Cancer

  2012cites this paper
• HER2 amplification in gastroesophageal adenocarcinoma: correlation of two antibodies using gastric cancer scoring criteria, H score, and digital image analysis with fluorescence in situ hybridization.

  2012cites this paper
• Targeted therapy for esophagogastric cancers: a review

  2012cites this paper
• Neoadjuvant chemo-radiotherapy for locally advanced esophageal cancer: A monocentric study

  2012cites this paper
• Fluorescence in situ hybridization mapping of esophagectomy specimens from patients with Barrett's esophagus with high-grade dysplasia or adenocarcinoma.

  2012cites this paper
• Phosphorylation of signal transducer and activator of transcription 3 (STAT3) correlates with Her-2 status, carbonic anhydrase 9 expression and prognosis in esophageal cancer

  2012cites this paper
• Molecular Pathology of Gastrointestinal Cancer.

  2012cites this paper
• Expression status of fatty acid synthase (FAS) but not HER2 is correlated with the differentiation grade and prognosis of esophageal carcinoma.

  2012cites this paper
• Clinicopathological characteristics of human epidermal growth factor receptor 2-positive Barrett's adenocarcinoma.

  2012cites this paper
• Definitive chemoradiotherapy for esophageal carcinoma.

  2012cites this paper
• Relationship between HER-2 overexpression and brain metastasis in esophageal cancer patients.

  2012cites this paper
• Esophageal Cancer - Cell and Molecular Biology, Biomarkers, Nutrition and Treatment

  2012cites this paper
• Gastroesophageal Reflux Disease: Molecular Predictors in Neoplastic Progression of Barrett's Esophagus

  2012cites this paper
• Expresión de Her-2/neu en adenocarcinoma gástrico. Experiencia de 10 años (2001-2011) en la Unidad Médica de Alta Especialidad No. 25, Centro Médico Nacional Noreste

  2012cites this paper
• Clinical issues in oesophageal adenocarcinoma: could DNA copy number hold the key?

  2012cites this paper
• Oesophago-Gastric Cancer

  2012cites this paper
• RADIATION THERAPY ONCOLOGY GROUP RTOG 1010 A PHASE III TRIAL EVALUATING THE ADDITION OF TRASTUZUMAB TO TRIMODALITY TREATMENT OF HER2-OVEREXPRESSING ESOPHAGEAL ADENOCARCINOMA NCI-Supplied Agent: Trastuzumab (NSC 688097; IND 6667) RTOG Study Chairs (Study Chairs continued on page 2)

  2011cites this paper
• Targeted Therapies for Metastatic Esophagogastric Cancer

  2011cites this paper
• Discovery of New Molecular Subtypes in Oesophageal Adenocarcinoma

  2011cites this paper
• Molecular Imaging for Guiding Oncologic Prognosis and Therapy in Esophageal Adenocarcinoma

  2011influential citation
• Trastuzumab has anti-metastatic and anti-angiogenic activity in a spontaneous metastasis xenograft model of esophageal adenocarcinoma.

  2011cites this paper
• HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH)

  2011cites this paper
• The dichotomy in carcinogenesis of the distal esophagus and esophagogastric junction: intestinal-type vs cardiac-type mucosa-associated adenocarcinoma

  2011cites this paper
• perspective on the role of targeted therapies in gastroesophageal cancer

  2011cites this paper
• HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma

  2011cites this paper
• HER‐2 status in primary oesophageal cancer, lymph nodes and distant metastases

  2011cites this paper
• Novel Immunotherapeutic Strategies of Gastric Cancer Treatment

  2011cites this paper
• HER-2/neu Gene Amplification in Esophageal Adenocarcinoma and Its Influence on Survival

  2011cites this paper
• Magen-Darm-Trakt

  2011cites this paper
• Her-2 in gastroesophageal cancer: pathobiology, diagnostic and therapeutic implications

  2011cites this paper
• Update on HER2 testing for breast and upper gastrointestinal tract cancers.

  2011cites this paper
• Early events during neoplastic progression in Barrett's esophagus

  2011cites this paper
• Expression of Her-2 in Carcinomas of the Esophagus

  2010cites this paper
• Distinct Role of Kruppel-like Factor 11 in the Regulation of Prostaglandin E2 Biosynthesis

  2010cites this paper
• Molecular determinants of metaplastic and neoplastic transformation in the esophageal epithelium.

  2010cites this paper
• Brush cytology vs. endoscopic biopsy for the surveillance of Barrett's esophagus.

  2010cites this paper
• HER-2/neu Testing and Therapy in Gastroesophageal Adenocarcinoma

  2010cites this paper
• Genetics in the Pathogenesis of Esophageal Cancer: Possible Predictive and Prognostic Factors

  2010cites this paper
• Tumors of the Esophagus

  2010cites this paper
• Current diagnosis and future impact of micrometastases for therapeutic strategies in adenocarcinoma of the esophagus, gastric cardia, and upper gastric third.

  2010cites this paper
• TOPOIIα and HER-2/neu overexpression/amplification in Barrett’s oesophagus, dysplasia and adenocarcinoma

  2010cites this paper
• Low Level of Her-2 Locus Amplification by Fluorescent In Situ Hybridization Does Not Correlate with Her-2 Protein Overexpression by Immunohistochemistry in Barrett's Esophagus

  2010cites this paper
• Gene amplification of ERBB2 and EGFR in adenocarcinoma in situ and intramucosal adenocarcinoma of Barrett's esophagus

  2010cites this paper
• Esophageal Adenocarcinoma: Treatment Modalities in the Era of Targeted Therapy

  2010cites this paper
• A role for iron in oesophageal adenocarcinoma

  2010cites this paper
• Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: predictors of progression and prognosis.

  2010cites this paper
• Esophagogastric cancer: targeted agents.

  2010cites this paper
• [Prognostic and predictive factors of oesophageal carcinoma].

  2009cites this paper
• Barrett esophagus and esophageal adenocarcinoma

  2009cites this paper
• Review: Integration of targeted agents in the neo-adjuvant treatment of gastro-esophageal cancers

  2009cites this paper
• ERBBs in the gastrointestinal tract: recent progress and new perspectives.

  2009cites this paper
• Esophageal adenocarcinoma arising in Barrett esophagus.

  2009cites this paper
• Assessment of a HER2 scoring system for gastric cancer: results from a validation study

  2008cites this paper